Phase 2a,Randomised,Double-Blind,Placebo-Cont, 2-Part Study in CC & AC [COVID-19]

• Research type

  Research Study

• Full title

  A Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants with Chronic or Acute Cough

• IRAS ID

  292551

• Contact name

  Jacky Smith

• Contact email

  jacky.smith@manchester.ac.uk

• Sponsor organisation

  Nocion Therapeutics, Inc.

• Eudract number

  2020-004715-27

• Clinicaltrials.gov Identifier

  NA, NA

• Duration of Study in the UK

  1 years, 3 months, 16 days

• Research summary

  Study summary - This phase 2a clinical trial is designed to investigate the safety, tolerability, and efficacy of NOC-100, an experimental medicinal product, to treat cough, regardless of the cause of the cough. NOC-100 contains a novel charged sodium channel blocker (CSCB), which has the potential to treat common neuroinflammatory conditions, such as the cough response. NOC-100 is designed to target the location of inflamed nociceptors that initiate cough and stop them from eliciting a cough response.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  20/HRA/5750

• Date of REC Opinion

  27 Jan 2021

• REC opinion

  Further Information Favourable Opinion